AB0623 RATE AND PREDICTIVE FACTORS ASSOCIATED WITH SUSTAINED REMISSION IN IDIOPATHIC INFLAMMATORY MYOSITIS

Background: There is a paucity of evidence based therapies for reactive arthritis(ReA). Data is limited for anti-TNF drugs usage [Table 1] with even less data on biosimilars. Objectives: To find out the outcomes of etanercept biosimilars (ETN-b) use in ReA Methods: A retrospective review of patients meeting the Braun criteria5 for probable ReA helped identify patients on ETN-b. Patients with less than 1 year follow-up and those who had received less than 5 doses of ETN were excluded. Biological naive patients who had completed at least 1 year follow-up were included as controls. Baseline and current status was compared between these two groups. Results: Of 94 identified ReA patients, 11(11.7%) had received ETN-b and 10 met the case definition. Five each had received one of two ETN-b. 30 were available as controls. All cases had been documented as refractory ReA. Amongst cases, 7 patients had resolution of ReA; 2 had relapsing courses and 1 persistent arthritis. Four were in remission off all drugs. Controls has similar proportions [Table 2]. There were no infections or adverse effects recorded during follow-up. Conclusion: All 10 patients responded. 40% achieved drug free remission. Thus, ETN-b appear safe and effective for ReA refractory to conventional therapy. References: [1]Flagg SD, Meador R, et al. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum. 2005;53(4):613-7 [2]Meyer A, Chatelus E, et al. Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum. 2011 May;63(5):1274-80 [3]Brinster A, Guillot X, et al. SAT0387 Anti Tnf Treatment of Reactive Arthritis. A Monocentric Experience. Ann Rheum Dis 2016;75:808 [4]Gupta V, Mohta P, et al. A retrospective case series of 12 patients with chronic reactive arthritis with emphasis on treatment outcome with biologics. Indian J Dermatol Venereol Leprol. 2019 [in print] [5]Braun J, Kingsley G, et al. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. 1999. J Rheumatol. 2000;27(9):2185-92 Disclosure of Interests: None declared